Emm Raises 7.7 M Euro to Launch World's First Smart Menstrual Cup

• Emm, a UK-based biowearable technology company, closed an oversubscribed Seed funding round of €7.7 million ($9 million)
• The funding will be used for launching the world's first smart menstrual cup and its connected app

The UK-based biowearable technology company, Emm, has gathered €7.7 million ($9 million) from an oversubscribed round of Seed funding in support of the launch of its smart menstrual cup and a mobile app connected with it.

Leading this round is Lunar Ventures, joined by the Labcorp Venture Fund, Tiny VC, BlueLion Global, Alumni Ventures, and several angel investors, such as Amar Shah, Vivek Garipalli, and Harpreet Rai. Additionally, it has non-dilutive funding via grants focused on women's health innovation.

Founder and CEO Jenny Button said menstruation has been largely ignored by the wearables market, despite being often referred to as the “fifth vital sign,” and underscored Emm's focus on delivering objective, actionable health insights to users.

Along with this raise, several other developments were noted in Europe’s FemTech and health-wearable ecosystem, including a €7.8 million Seed round for hormone tracking firm Hormona; a €250k pre-Seed round from YON E Health for its smart vaginal-health device; and a €14 million Series A for a connected patient-monitoring patch at RDS.

Together, these investments bring around €22 million in funding across the women’s and connected-health technologies of 2025.

Emm's Seed round places the company among the larger early-stage raises in the sector, its focus on menstrual biowearables setting it apart from other recent innovations.

Board Chair Grace E. Colón pointed out that the Emm platform has the potential to support both biological sampling and data generation for researchers and biotech organizations working in women's health.

Founded in 2020, Emm has spent the last five years developing its smart menstrual cup by integrating advanced sensor technology with medical-grade silicone.

Meanwhile, data from baseline cycles is collected over time through the accompanying app, helping users more effectively identify patterns and discuss symptoms with healthcare professionals within several cycles.

It is expected to launch in the UK in early 2026 and already has an open waitlist, with expansion to other markets planned.

Lunar Ventures' Partner Mick Halsband commented that Emm solves major engineering challenges and is likely to set new standards regarding data and care in menstrual health.

This new funding will back Emm in bringing the product to market, continuing to advance clinical development, and contributing to better research, diagnosis, and treatment of menstrual and reproductive health conditions.

The company says that despite the fact that menstrual symptoms are incredibly pervasive, reliable methods of measurement and tracking have remained limited.

Megann Vaughn Watters, lab operations manager for Labcorp, said the company values technologies that provide better access to health data for individuals, and expressed support for Emm's efforts to improve the understanding and management of reproductive health conditions.